Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.47 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23380264 | 0.81 | HRH3 (0.60) | ALDH1A1HRH3KMT2A | |
| SCHEMBL20202210 | 0.79 | OPRK1 (0.57) | OPRK1OPRM1OPRD1 | |
| SCHEMBL6223358 | 0.79 | ALDH1A1 (0.60) | ALDH1A1HRH3 | |
| SCHEMBL492101 | 0.78 | HRH3 (0.69) | ALDH1A1HRH3KMT2A | |
| SCHEMBL20202207 | 0.78 | OPRK1 (0.56) | OPRK1OPRM1OPRD1 | |
| SCHEMBL20202212 | 0.78 | OPRK1 (0.56) | OPRK1OPRM1OPRD1 | |
| SCHEMBL30007295 | 0.78 | OPRK1 (0.56) | OPRK1OPRM1OPRD1 | |
| SCHEMBL20187332 | 0.78 | OPRK1 (0.56) | OPRK1OPRM1OPRD1 | |
| SCHEMBL20202205 | 0.78 | OPRK1 (0.56) | OPRK1OPRM1OPRD1 | |
| SCHEMBL20202198 | 0.78 | OPRK1 (0.56) | OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.